CML Multiple Sclerosis

» Advanced search

Paper of the Month - October, 2009

• View Archive »

  • Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood–brain barrier in vitro. - May, 2012
    Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label Phase 2a proof-of-concept study. - April, 2012
    Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. - March, 2012
    Pathophysiology of multiple sclerosis and the place of teriflunomide. - February, 2012
    Permanent tremor reduction during thalamic stimulation in multiple sclerosis. - January, 2012
    Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. - December, 2011
    Demographic and clinical characteristics of malignant multiple sclerosis. - November, 2011
    Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. - October, 2011
    Reorganization in cognitive networks with progression of multiple sclerosis: insights from fMRI. - September, 2011
    The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. - August, 2011
    Purinergic signalling at the plasma membrane: a multipurpose and multidirectional mode to deal with amyotrophic lateral sclerosis and multiple sclerosis. - July, 2011
    MRI only conversion to multiple sclerosis following a clinically isolated syndrome. - June, 2011
    Switching multiple sclerosis patients with breakthrough disease to second-line therapy. - May, 2011
    Fingolimod for the treatment of relapsing multiple sclerosis. - April, 2011
    Headache in multiple sclerosis. - March, 2011
    Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. - February, 2011
    Early diffuse demyelinating lesion in the cervical spinal cord predicts a worse prognosis in relapsing-remitting multiple sclerosis. - January, 2011
    Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. - December, 2010
    Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry - November, 2010
    Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. - October, 2010
    Preserved brain adaptive properties in patients with benign multiple sclerosis. - September, 2010
    A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis - August, 2010
    Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. - July, 2010
    Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. - June, 2010
    Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. - May, 2010
    Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. - April, 2010
    Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. - March, 2010
    In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. - February, 2010
    Progressive multifocal leukoencephalopathy after natalizumab monotherapy. - January, 2010
    Accumulation of cortical lesions in MS: relation with cognitive impairment. - December, 2009
    Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. - November, 2009
    Opportunistic infections and other risks with newer multiple sclerosis therapies. - October, 2009
    Diffusely abnormal white matter in chronic multiple sclerosis. - September, 2009
    The relation between inflammation and neurodegeneration in multiple sclerosis brains. - August, 2009
    Mitochondrial changes within axons in multiple sclerosis. - July, 2009
    IFN-beta 1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. - June, 2009
    Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. - May, 2009
    Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a Phase I/II study. - April, 2009
    Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. - March, 2009
    Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. - February, 2009
    Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. - January, 2009